10 Best Performing Stocks of Q1 2026 to Watch for Q2

7. Tango Therapeutics, Inc. (NASDAQ:TNGX)

Q1 2026 Performance: 134.27%

Tango Therapeutics, Inc. (NASDAQ:TNGX) is one of the best-performing stocks of Q1 2026 to watch for Q2. On March 9, Stifel increased its price target on Tango Therapeutics, Inc. (NASDAQ:TNGX) from $15 to $24 while keeping a Buy rating on the stock.

The firm pointed to recent progress in PRMT5 inhibitors and RAS(ON) combinations, which the firm believes lowers the risk for the company’s first-line pancreatic ductal adenocarcinoma opportunity. Stifel also included risk-adjusted first-line pancreatic ductal adenocarcinoma credit into its financial model for Tango Therapeutics, Inc. (NASDAQ:TNGX).

Earlier, on March 5, Jefferies also increased its price target on Tango Therapeutics, Inc. (NASDAQ:TNGX) from $14 to $18 and maintained its Buy rating on the stock.

Jefferies pointed to the company’s supply agreement with ERAS for pan-RAS. The research firm pointed out that upcoming topline data from Revolution Medicines on daraxonrasib, expected in the first half of 2026 for second-line pancreatic ductal adenocarcinoma, could set a new standard of care.

Tango Therapeutics, Inc. (NASDAQ:TNGX) is a clinical-stage biotechnology company focused on the discovery of novel drug targets and the delivery of precision medicine for the treatment of cancer.